SAN DIEGO, January 31, 2012 – Profil® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today the appointment of Dr. John Amatruda, a pharmaceutical research executive, and Dr. Jerrold Olefsky, professor of medicine at the University of California, San Diego, to its Board of Directors.

Profil Institute the Only Clinical Research Institute Exhibiting at Annual Meeting, Strengthening Company’s Position as a Leading Specialized Provider of Phase I Clinical Trials in Diabetes

SAN DIEGO, September 12, 2011 – Profil® Institute for Clinical Research, Inc., a specialized contract research institute optimizing early phase diabetes, obesity and cardiometabolic drug development, will present key clinical and experimental diabetes and insulin-related research at the European Association for the Study of Diabetes (EASD) 47th Annual Meeting being held September 12 - 16 in Lisbon, Portugal.

SAN DIEGO, June 16, 2011 – Profil® Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today the appointment of Dr. Andrew Krentz as Senior Director of Scientific Services. Dr. Krentz, who is currently a senior scientific consultant for Profil Institute, will take on his new position in October following his relocation from the UK to San Diego. In his new role he will oversee Profil Institute’s scientific services department and its integrated, science-driven approach from clinical trial protocol design to the publication of metabolic studies.

SAN DIEGO and SAN CARLOS, CA, June 8, 2011 – Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa’s modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.

SAN DIEGO, April  20, 2011 – Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today its sponsorship of the American Diabetes Association’s Tour de Cure, an annual nationally recognized cycling event on Saturday, May 7 in Cardiff By The Sea.

SAN DIEGO, April 07, 2011 /PRNewswire/ – Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today that the American Diabetes Association’s CEO Larry Hausner visited Profil Institute’s office to acknowledge the contributions that the company has made to support the Association at a national and local level.

SAN DIEGO, January  27, 2011 /PRNewswire/ – Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today that CEO Dr. Marcus Hompesch is an invited speaker at the Ramanbhai Foundation 5th International Symposium and ISCR’s 4th Annual Clinical Research Conference in February. 

SAN DIEGO, November 22, 2010 /PRNewswire/ – Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company’s early phase diabetes and obesity clinical trials.

SAN DIEGO, October 7, 2010 /PRNewswire/ – Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the initiation of patient screening in Orange County for clinical trial eligibility at the company’s San Diego clinical facility.  

SAN DIEGO, September 15, 2010 – Profil™ Institute for Clinical Research, Inc. will present key clinical and experimental diabetes and insulin-related research at the European Association of the Study of Diabetes (EASD) 46th Annual Meeting being held September 20 – 24 in Stockholm, Sweden.  Profil Institute’s presence as a contributor of scientific presentations emphasizes the company’s position as a specialized contract research institute optimizing early phase diabetes, obesity and cardiometabolic drug development.